LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NUWE
Nuwellis, Inc.
There isn't enough reported data to score NUWE yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NUWE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
NUWE's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NUWE PE Valuation
NUWE has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NUWE Forward outlook
There aren't enough analyst estimates for NUWE to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
NUWE Earnings Per Share
NUWE and LLY do not have enough comparable growth data to identify a winner.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NUWE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NUWE on profitability, with a higher operating margin.
NUWE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | -0.2% |
| Q2 2026 | $2M | +14% |
| Q1 2026 | $2.4M | +26% |
| Q4 2025 | $2.4M | +4.4% |
| Q3 2025 | $2.2M | -6.3% |
| Q2 2025 | $1.7M | -21% |
| Q1 2025 | $1.9M | +2.5% |
| Q4 2024 | $2.3M | -9% |
NUWE's revenue is growing: $2M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -93% | +29 points |
| Q2 2026 | -161% | +7.5 points |
| Q1 2026 | -190% | -29 points |
| Q4 2025 | -101% | +2 points |
| Q3 2025 | -122% | -57 points |
| Q2 2025 | -168% | -63 points |
| Q1 2025 | -161% | +95 points |
| Q4 2024 | -103% | +38 points |
NUWE's operating margin was −93% last quarter, up 29 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NUWE on cash generation, producing positive trailing cash flow while its opponent burns cash.
NUWE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3M | +$282K |
| Q2 2026 | -$3.2M | -$1.1M |
| Q1 2026 | -$3.1M | -$606K |
| Q4 2025 | -$3M | -$1.5M |
| Q3 2025 | -$3.2M | -$790K |
| Q2 2025 | -$2.1M | +$677K |
| Q1 2025 | -$2.5M | +$355K |
| Q4 2024 | -$1.5M | +$1.2M |
NUWE has burned cash in almost every quarter: −$12M over the past year, against −$9M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NUWE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NUWE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +206% | +13.6K shares |
| 1 year | +2984% | +19.5K shares |
| 3 years | +671167% | +20.1K shares |
NUWE has 20,138 diluted shares, up 2984% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NUWE Net Leverage
NUWE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NUWE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.7 | Oversold |
| Stochastic | 12.8 | Oversold |
NUWE's weekly RSI is 26 (oversold) and its Stochastic is 13 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NUWE PE vs Healthcare Sector
NUWE has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NUWE on trend strength, trading above more of its moving averages.
NUWE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.32 | 5.5% below |
| 20 week MA | $11.2 | 55% below |
| 50 week MA | $277.8 | 98% below |
| 100 week MA | $4,134.8 | 100% below |
| 200 week MA | $387,796.3 | 100% below |
NUWE is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NUWE on returns for 2026, with the stronger performance.
NUWE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,168,052,886.0 | $339,415,650.0 | -71% |
| 2021 | $339,415,650.0 | $56,955,150.0 | -83% |
| 2022 | $56,955,150.0 | $3,519,180.0 | -94% |
| 2023 | $3,519,180.0 | $268,985.8 | -92% |
| 2024 | $268,985.8 | $15,479.1 | -94% |
| 2025 | $15,479.1 | $642.6 | -96% |
| 2026 YTD | $642.6 | $5.03 | -99% |
NUWE has finished every year since 2020 lower, and it's down 99% so far in 2026.